We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Atorvastatin in Moderate Active Crohns Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00454545
Recruitment Status : Completed
First Posted : March 30, 2007
Last Update Posted : October 22, 2007
Information provided by:
Skane University Hospital

March 29, 2007
March 30, 2007
October 22, 2007
October 2006
Not Provided
Inflammatory markers in plasma before and after treatment.
Same as current
Complete list of historical versions of study NCT00454545 on ClinicalTrials.gov Archive Site
Change in clinical activity index and mucosal inflammation after treatment.
Same as current
Not Provided
Not Provided
Atorvastatin in Moderate Active Crohns Disease
Not Provided
Open pilot study to collect information regarding the effect of atorvastatin on patients with active Crohns disease.
Not Provided
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Crohns Disease
Drug: Atorvastatin
Not Provided
Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One. 2009;4(5):e5263. doi: 10.1371/journal.pone.0005263. Epub 2009 May 6.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
October 2007
Not Provided

Inclusion Criteria:

  • Clinical diagnosis of Crohns disease
  • C-reactive protein level > 2 mg/L in absence of an infection
  • Fecal calprotectin > 250 mg/kg or CDAI > 150

Exclusion Criteria:

  • CDAI > 450
  • Prednisolone dosage above 15 mg/day
Sexes Eligible for Study: All
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Skane University Hospital
Not Provided
Principal Investigator: Olof Grip, MD, PhD Malmo University Hospital, Region Skåne
Study Chair: Anders Bredberg, MD, PhD Malmo University Hospital, Region Skåne
Study Chair: Gunnel Bredberg, MD, PhD Malmo University Hospital, Region Skåne
Skane University Hospital
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP